Flatiron Health

Overview

Flatiron Health is an oncology real-world evidence vendor built around OncoEMR, its oncology-specific electronic health record network. For manufacturers, the core question is whether Flatiron’s first-party community oncology data, AI-assisted abstraction, and evidence-generation tools fit the study question better than broader claims-scale or multi-therapeutic-area data vendors.

The public buyer signal is strongest in oncology RWE, external controls, treatment-pattern studies, market-access evidence, and clinical-development feasibility. Flatiron should be compared against other real-world-evidence vendors by oncology depth, data provenance, methods transparency, regulatory credibility, workflow usability, refresh cadence, and compliance controls.

Real-World Evidence Capability Model

The framework below standardizes how Rx Almanac evaluates real-world-evidence capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Flatiron Health is evaluated as oncology real-world evidence vendor built around OncoEMR, its oncology-specific electronic health record network.

Capability	Buyer should compare	Flatiron Health readout
Data assets and linkage coverage	Claims, EHR, registry, lab, mortality, genomic, provider, and patient-level linkage breadth.	Core coverage workflow. OncoEMR gives Flatiron first-party oncology EHR depth across 4,700+ providers and a 5.5M+ patient-record database.
Study design and causal inference	Protocol development, statistical methods, bias control, synthetic/external controls, and reproducibility.	Core study-design work. Strong fit for external control arms, trial feasibility, treatment-pattern studies, outcomes research, and oncology cohort design.
Regulatory, HTA, and payer evidence packages	FDA, EMA, NICE/HTA, payer value dossiers, label expansion, and post-market evidence use cases.	Core regulatory evidence. Flatiron has a long regulatory-evidence track record and has published the VALID framework for evaluating AI-extracted oncology RWD.
Oncology, rare disease, and specialty depth	Fit for small populations, biomarkers, longitudinal oncology records, rare-disease cohorts, and specialty-drug endpoints.	Core oncology and rare-disease evidence. Oncology and hematology are the center of gravity, including Panoramic datasets and global prostate / hematology cohorts.
Analytics platform and self-service workflow	User-facing software, cohort builders, query tools, dashboards, and analyst service model.	Core analytics workflow. Flatiron Telescope adds natural-language cohort building and outcomes analytics on top of the oncology database.
Privacy, governance, and refresh cadence	HIPAA controls, de-identification, data rights, governance, update frequency, and auditability.	Confirm governance control in the RFP. Ask specifically about study-level data rights, auditability, refresh timing, cross-border access, and manufacturer data-use controls.

Buyer Fit

• Shortlist when: Use Flatiron when the product question is oncology-specific and the team needs decision-grade RWE for regulators, payers, HTA bodies, medical affairs, or clinical-development planning.
• Best-fit teams: Clinical development, regulatory affairs, HEOR, market access, medical affairs, and evidence-generation groups at oncology manufacturers or biotechs.
• Therapy and product fit: Strongest for oncology, hematology, cell therapy, gene therapy, biologics, and small-molecule oncology products.
• Commercial fit: Assume an RFP-led custom scope. Define whether the work is dataset access, platform workflow, evidence services, an external-control project, or an integrated package.
• Implementation diligence: Confirm data provenance, cohort refresh, endpoint definitions, abstraction method, tokenization/linkage, regulatory methods documentation, publication rights, and what work is self-service versus services-led.

Differentiators

• OncoEMR data flywheel: Flatiron owns an oncology workflow surface rather than only licensing third-party data, which can give it deeper longitudinal treatment and outcomes context in community oncology.
• AI-curated oncology endpoints: The VALID framework and LLM-based progression extraction strengthen the case that Flatiron is competing on evidence quality and speed, not just database size.
• Flatiron Telescope: Natural-language cohort and outcomes analytics makes the platform more usable for non-technical evidence teams that need feasibility, market-sizing, or outcomes readouts quickly.
• Global evidence model: Panoramic datasets, the Lifebit-powered trusted research environment, and Flatiron FORUM support multinational oncology RWE where data cannot simply move across borders.
• Point-of-care ecosystem: Diagnostic and access integrations with partners such as Abbott, Natera, Adaptive Biotechnologies, TailorMed, and Paradigm Health make OncoEMR a channel for oncology workflow expansion.

RFP Questions

• Which oncology data elements are native to OncoEMR, which are abstracted, and which come from linked or partner sources?
• How are AI-extracted endpoints validated against human abstraction, and what documentation is available for regulators, HTA bodies, or journal review?
• How can the vendor support the exact tumor type, biomarker, line of therapy, geography, and outcome window needed for the study?
• How fast can cohorts refresh after a new approval, label update, guideline change, or major trial readout?
• What parts of Flatiron Telescope are self-service, and where does the Flatiron team still need to design, run, or interpret the analysis?
• How are manufacturer data-use controls, cross-border access, and audit trails handled for sensitive oncology evidence work?

Recent Activity

• 2026: Flatiron launched Flatiron Telescope, an AI-powered platform for cohort building and oncology insights in minutes.
• 2026: Flatiron expanded global prostate cancer Panoramic datasets spanning the US, UK, and Germany under a common data model.
• 2026: Abbott integrated precision oncology portfolio ordering and results into OncoEMR.
• 2026: TailorMed partnered with Flatiron to embed medication access and financial-assistance workflow into OncoEMR.
• 2025: Flatiron expanded hematology Panoramic datasets across multiple myeloma and B-cell lymphoma populations.
• 2025: Flatiron continued international expansion across the UK, Germany, and Japan through a federated research model.